Deutsche Märkte öffnen in 6 Stunden 1 Minuten

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
4,1700-0,1400 (-3,25%)
Börsenschluss: 04:00PM EST
4,2200 +0,05 (+1,20%)
Nachbörse: 07:59PM EST

Sorrento Therapeutics, Inc.

4955 Directors Place
San Diego, CA 92121
United States
858 203 4100


Leitende Angestellte

Dr. Henry H. Ji Ph.D.Chairman, Pres, CEO & Interim CFO1,75MN/A1964
Mr. Brian SunSr. VP, Gen. Counsel & Corp. Sec.N/AN/AN/A
Mr. William J. FarleyVP of Sales & Bus. Devel.N/AN/A1955
Dr. Michael A. RoyalSVP & Chief Medical OfficerN/AN/A1954
Dr. Alexis NahamaSr. VP & Head of RTX ProgramN/AN/AN/A
Dr. Mark R. BrunswickSr. VP of Regulatory AffairsN/AN/AN/A
Dr. Shawn Sahebi Ph.D.Sr. VP of Strategy & AnalyticsN/AN/AN/A
Mr. Brian CooleySr. VP of Lymphatic Drug Delivery BU LeaderN/AN/AN/A
Dr. Robert D. Allen Ph.D.Sr. VP of Antiviral & ImmunotherapyN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.


Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Corporate Governance

Sorrento Therapeutics, Inc.s ISS Governance QualityScore, Stand 26. September 2021, lautet 9. Die grundlegenden Scores sind Audit: 10, Vorstand: 8, Shareholderrechte: 7, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.